INTENSITY THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
INTENSITY THERAPEUTICS, INC. (INTS) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $60.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $60.00K, a 91.40% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-03-31 was $7.00K, a 58.82% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-09-30 was $301.00K, a 267.07% increase year-over-year.
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-06-30 was $698.00K.
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $412.00K, a 28.35% increase from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $321.00K, a 90.57% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2023 was $3.40M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.00K 10-Q · filed 2026-08-11 | $67.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $7.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $412.00K 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $301.00K 10-Q · filed 2025-11-06 | $999.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.02M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $698.00K 10-Q · filed 2026-08-11 | $715.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $17.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $321.00K 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $82.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $3.40M 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |